Salas-Benito, D. (Diego)

Filtering

20202

Settings

Author search.filters.isAuthorOfPublication.7c426b6e-b417-4fa9-aa90-5ff4469223fa

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Inflammation and immunity in ovarian cancer
    (2020) Glez-Vaz, J. (Javier); Vercher-Herráez, E. (Enric); Hervas-Stubbs, S. (Sandra); Tamayo, I. (Ibon); Salas-Benito, D. (Diego); Conde, E. (Enrique)
    The standard first-line therapy for ovarian cancer is a combination of surgery and carboplatin/paclitaxel-based chemotherapy. Patients with longer survival and improved response to chemotherapy usually present T-cell inflamed tumours. The presence of tumour-infiltrating T cells (TILs) notably varies among the different subtypes of ovarian tumours, being highest in high-grade serous ovarian carcinoma, intermediate in endometrioid tumours, and lowest in low-grade serous, mucinous and clear cell tumours. Interestingly, the presence of TILs is often accompanied by a strong immunosuppressive tumour environment. A better understanding of the immune response against ovarian cancer and the tumour immune evasion mechanisms will enable improved prognostication, response prediction and immunotherapy of this disease. This article provides an overview of some ovarian cancer cell features relevant for antitumour response, such as tumour-associated antigens, including neoantigens, expression of inhibitory molecules, and other mechanisms of immune evasion. Moreover, we describe relevant immune cell types found in epithelial ovarian tumours, including T and B lymphocytes, regulatory T cells, natural killer cells, tumour-associated macrophages, myeloid-derived suppressor cells and neutrophils. We focus on how these components influence the burden of the tumour and the clinical outcome.
  • Thumbnail Image
    Single-institution experience in clinical trials during the COVID-19 pandemic in Spain: Not so bad after all?
    (ASCO, 2020) Reis, J. (Joana); Alfonso-Piérola, A. (Ana); Ponz-Sarvise, M. (Mariano); Rodriguez-Otero, P. (Paula); Salas-Benito, D. (Diego); Giraldez, M. (Miriam); Azanza, J.R. (José Ramón)
    The impact of the COVID-19 outbreak in Spain during March-April 2020 has been unbalanced throughout the different regions of the country. The alarm status defined by the government on March 14, and still in place at the time of this writing, has transformed the country in different perspectives, including care of patients with cancer.1 In many centers, clinical trial activity was suspended, because it was not considered a priority under the health care challenge of the COVID-19 pandemic.2 Nevertheless, experimental therapy is the only and/or best therapeutic option for many patients with cancer.